Samsung Electronics is zeroing in on the digital health market with new artificial intelligence (AI) wearables. The Galaxy Watch 7, set for release in the second half of this year, is expected to offer blood glucose monitoring in addition to its earlier capability to detect sleep apnea. When combine
Samsung Bioepis announced on April 23 that it has received final marketing authorization from the European Commission (EC) for Pyzchiva (project name SB17, ustekinumab), a biosimilar to Stelara. Pyzchiva’s active substance name is ustekinumab.Pyzchiva is the fourth autoimmune disease treatment devel
HLB has opened an office in the Cambridge Innovation Center (CIC) in Boston, Massachusetts, in the United States, to strengthen its collaboration with global pharmaceutical giants and to support its subsidiaries’ expansion into overseas markets.Through the Boston office, HLB plans to strengthen comm
The collective net worth of Korea’s 50 Richest on the 2024 Forbes list rose slightly to US$115 billion from $106 billion, amid the country’s global chipmaking ambitions. The complete list can be found at www.forbes.com/korea, as well as in the April/May issue of Forbes Asia and the May issue of Forb
Celltrion announced on April 11 that “Zymfentra” (the U.S. brand name for Remsima), the world’s first subcutaneous formulation of infliximab for the treatment of autoimmune diseases developed in-house, has completed its formulation patent registration with the United States Patent and Trademark Offi
GC Cell, a fully integrated cell therapy pioneer, has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug ‘Immuncell-LC’ at the AACR Annual Meeting 2024 th
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Recent ELCC data released by J&J proves that the expanded adverse reactions seen during phase III trials of Mariposa can be managed. With approval expected mid-year, now is the time to pay attention
Celltrion announced on March 25 that it has received a recommendation for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) for the full label of its Xolair (active ingredient: omalizumab) biosimilar “CT-P39.”The original
Controversy over AliExpress’ and Temu’s harmful content for teenagers has not subsided.Despite constant criticism from Korean consumer organizations, the two Chinese e-commerce giants’ measures have been insufficient, and responses came late from the Korean government.According to a recent report, a
Hanmi Pharmaceutical announced on March 18 that it will unwrap 10 new research projects, the most in the industry, in the American Association for Cancer Research 2024 (AACR 2024), which will run in San Diego of the United States from April 5 to 10.First, Hanmi Pharmaceutical will present the result
The growth of leading domestic companies in the medical AI field is becoming evident, as the number of clinical trial applications, approvals, and authorizations rapidly increases. Medical AI involves AI trained on various disease data, analyzing patients’ Computed Tomography (CT) scans or Magnetic
Chinese online shopping platforms AliExpress, Temu, Shine and other overseas business operators over a certain size will be required to have representatives in Korea. This new policy is aimed at making them responsible for consumer protection.Unlike AliExpress, which currently has a legal entity in
LG Group has decided to embark on joint AI research and development with The Jackson Laboratory, a world-renowned genome research institution based in the United States, to unlock the secrets of Alzheimer’s disease and cancer.LG AI Research and The Jackson Laboratory have signed a recent contract fo
Celltrion announced on March 11 that it has completed the application process for U.S. Food and Drug Administration (FDA) approval of “CT-P39,” a biosimilar to the asthma and chronic idiopathic urticaria treatment XOLAIR. The company applied for product approval based on the results of a global Phas
Samsung Bioepis announced on March 10 the clinical results of SB5, a biosimilar to the blockbuster drug Humira, at the American Academy of Dermatology (AAD) Annual Meeting held in San Diego, California, in the U.S. on Feb. 8 (local time). This study aimed to verify whether SB5 can be interchangeably
Samsung Biologics announced on March 6 that it has entered into a contract manufacturing organization (CMO) production agreement valued at 381.9 billion won (US$287.0 million) with UCB, which is headquartered in Belgium. This agreement is an increase to the contract signed in 2017 with the company,
HLB disclosed on March 4 that its board of directors has approved the issuance of 60 billion won in convertible bonds to domestic private equity funds and others. The primary purpose of this fundraising is to secure operational funds. Although the company currently holds over 65 billion won in cash
Hugel, Inc. announced on March 4 that it has obtained product approval from the U.S. Food and Drug Administration (FDA) for its botulinum toxin product Letybo in 50-unit and 100-unit dosages on Feb. 29, local time. This FDA approval marks Hugel as the first and only company in South Korea, and the t
Lee Woong-yeol, the honorary chairman of Kolon Group, along with the corporation itself, have been indicted on charges related to the tampering of the ingredient of Invossa Injection, a treatment for osteoarthritis. The first trial is anticipated to conclude in the first half of the year, with a dec
The author is an analyst for NH Investment & Securities. He can be reached at bk@nhqv.com -- Ed.Global stock markets have rallied of late, with the S&P500 surging for four months in a row. In February, the Kospi has outperformed other major markets. But, the fast market growth is likely to bolster p